Table 2

Sociodemographic and clinical characteristics of the subgroup of PTSD patients and control subjects for which we analyzed cytokine production by PBMCs
Variables PTSD Controls p
(n = 16) (n = 18)
Agea (y) 36.1 ± 9.5 26.7 ± 7.4 .003
Sex (f/m) 7/9 11/7 .31
Region of Origin (%) .16
  Africa 18.7% 5.6%
  Balkan 25.0% 55.5%
  Middle East 65.3% 38.9%
Smokers (%) 37.5% 16.7% .17
Psychotropic medication (%) 31.2% 0% .01
  Hypnotics 0% 0%
  Anxiolytics 12.5% 0%
  Antidepressives 31.2% 0%
  Neuroleptics 6.2% 0%
Contraceptives (%) 0% 16.7% .23
Comorbid depression (%) 75.0% 0% <.0005
Number of traumatic event typesa
  War or torture events 11.0 ± 5.8 1.8 ± 3.9 <.0005
  CAPS events 7.2 ± 1.7 3.3 ± 1.9 <.0005
CAPS Scorea 82.5 ± 16.5 7.0 ± 12.8 <.0005
HAMD Scorea 25.2 ± 8.1 4.6 ± 6.3 <.0005
SOMS Scorea 28.4 ± 13.8 4.9 ± 8.2 <.0005

aData are presented as mean ± SD.

*For pair-wise group comparisons of continuous variables, we performed t-tests, differences of categorical variables were evaluated by applying χ2 tests for independence. (Y) = years; (f) = female; (m) = male; CAPS, Clinician Administered PTSD Scale; HAM-D, Hamilton Depression Rating Scale; SOMS-7, Screening for Somatoform Symptoms-7.

Gola et al.

Gola et al. BMC Psychiatry 2013 13:40   doi:10.1186/1471-244X-13-40

Open Data